Ultralife Corporation (ULBI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ULBI SEC filings page.
Ultralife Corporation (ULBI) reported $187.2M in revenue over the twelve months to Jun 30, 2026, up 4.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expanded, but rising operating costs turned a profitable FY2024 into an operating loss despite continued cash generation.
Earnings and cash temporarily diverged: FY2025 produced operating cash flow of$11.0M and free cash flow of$7.1M alongside a net loss of$5.9M . That is weaker cash conversion than FY2024, when operating cash flow reached$16.6M and free cash flow was$14.7M , so positive cash generation did not prevent a sharp deterioration in reported profitability.
The margin problem is below gross profit, not primarily at the product-cost level: revenue increased to
The balance sheet remains liquid but more debt-funded than in earlier years: the current ratio was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ultralife Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ultralife Corporation held $9.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $11.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Ultralife Corporation scores 86/100 among other emerging companies.
Ultralife Corporation had 17M shares outstanding at the end of fiscal year 2025, against 17M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Ultralife Corporation scores 70/100 among other emerging companies.
Ultralife Corporation spent $10.4M on research and development in fiscal year 2025, which was 5.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Ultralife Corporation scores 25/100 among other emerging companies.
Ultralife Corporation reported revenue of $191.2M in fiscal year 2025, against $164.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Ultralife Corporation scores 55/100 among other emerging companies.
Not available for Ultralife Corporation, and counted as zero in the overall score.
Ultralife Corporation's cash, cash equivalents and investments came to $9.3M at the end of fiscal year 2025, against $86.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Ultralife Corporation scores 18/100 among other emerging companies.
Ultralife Corporation scores 1.63, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ultralife Corporation passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Ultralife Corporation reported a net loss of $5.9M while generating $11.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Ultralife Corporation reported an operating loss of $5.9M against $4.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Ultralife Corporation generated $47.9M in revenue in Q2 2026. This represents a decrease of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 1.0%.
Ultralife Corporation's EBITDA was $4.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.6% from the same quarter a year earlier. Against the prior quarter it is up 330.5%.
Ultralife Corporation reported $2.5M in net income in Q2 2026. This represents an increase of 189.3% from the same quarter a year earlier. Against the prior quarter it is up 663.9%.
Ultralife Corporation earned $15.00 per diluted share (EPS) in Q2 2026. This represents an increase of 200.0% from the same quarter a year earlier. Against the prior quarter it is up 600.0%.
Cash & Balance Sheet
Ultralife Corporation generated $735K in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 84.8% from the same quarter a year earlier. Against the prior quarter it is down 50.5%.
Ultralife Corporation held $6.7M in cash against $42.9M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Ultralife Corporation's gross margin was 28.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.6 percentage points.
Ultralife Corporation's operating margin was 7.2% in Q2 2026, reflecting core business profitability. This is up 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.6 percentage points.
Ultralife Corporation's net profit margin was 5.3% in Q2 2026, showing the share of revenue converted to profit. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.3 percentage points.
Ultralife Corporation's ROE was 1.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.
Capital Allocation
Ultralife Corporation invested $3.2M in research and development in Q2 2026. This represents an increase of 39.1% from the same quarter a year earlier. Against the prior quarter it is up 8.9%.
Ultralife Corporation invested $453K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 58.8% from the same quarter a year earlier. Against the prior quarter it is down 41.2%.
Not reported for Q2 2026.
ULBI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.9M-1.3% | $47.4M-6.5% | $48.5M+10.6% | $43.4M+21.5% | $48.6M+13.0% | $50.7M+21.0% | $43.9M-1.6% | $35.7M-9.6% |
| Cost of Revenue | $34.1M-7.8% | $37.3M-1.8% | $36.4M+9.5% | $33.8M+25.0% | $37.0M+17.6% | $38.0M+24.8% | $33.3M+0.3% | $27.0M-9.1% |
| Gross Profit | $13.9M+19.5% | $10.1M-20.7% | $12.1M+13.7% | $9.6M+10.8% | $11.6M+0.3% | $12.7M+11.1% | $10.6M-7.0% | $8.7M-11.2% |
| R&D Expenses | $3.2M+39.1% | $3.0M+23.2% | $2.8M+16.9% | $2.9M+35.9% | $2.3M+16.1% | $2.4M+36.9% | $2.4M+30.3% | $2.1M+12.4% |
| SG&A Expenses | $7.2M+2.5% | $7.4M+6.1% | $7.7M+14.1% | $7.7M+27.1% | $7.0M+24.4% | $6.9M+22.8% | $6.7M+13.7% | $6.1M+5.2% |
| Operating Income | $3.4M+52.3% | -$215K-106.3% | -$10.6M-819.5% | -$951K-286.1% | $2.3M-42.4% | $3.4M-16.3% | $1.5M-59.6% | $511K-76.1% |
| EBITDA | $4.8M+29.6% | $1.1M-76.7% | -$9.3M-450.5% | $468K-68.9% | $3.7M-25.5% | $4.8M-5.5% | $2.7M-42.5% | $1.5M-51.8% |
| Interest Expense | $839K-15.4% | $868K-15.9% | $937K+13.0% | $992K+473.4% | $992K+137.3% | $1.0M+98.5% | $829K+46.5% | $173K-70.5% |
| Income Tax | $468K+92.6% | -$192K-133.9% | -$2.8M-1150.8% | -$504K-781.1% | $243K-71.5% | $567K-19.3% | $262K-0.4% | $74K-83.4% |
| Net Income | $2.5M+189.3% | -$451K-124.2% | -$7.4M-3925.8% | -$1.2M-572.9% | $879K-70.4% | $1.9M-35.5% | $194K-93.2% | $258K-80.6% |
| EPS (Basic) | $15.00+200.0% | -$3.00-127.3% | -$35.09-193.3% | -$0.07-450.0% | $5.00+2677.8% | $11.00+13650.0% | $37.63+22035.3% | $0.02-75.0% |
| EPS (Diluted) | $15.00+200.0% | -$3.00-127.3% | -$35.09 | -$0.07-450.0% | $5.00 | $11.00 | $37.63 | $0.02-75.0% |
| Diluted Shares (Avg) | 17M+0.3% | 17M-0.1% | N/A | 17M-1.4% | 17M | 17M | N/A | 17M+3.5% |
ULBI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $216.2M-2.2% | $220.6M-1.4% | $216.9M-1.6% | $222.2M+28.9% | $221.0M+30.1% | $223.8M+23.9% | $220.5M+23.7% | $172.4M-2.1% |
| Current Assets | $107.2M+8.2% | $110.1M+8.5% | $105.8M+8.9% | $100.6M+16.4% | $99.0M+18.2% | $101.5M+7.6% | $97.2M+7.7% | $86.4M-3.5% |
| Cash & Equivalents | $6.7M-39.1% | $8.9M+2.0% | $9.3M+36.3% | $9.3M+36.7% | $10.9M+63.5% | $8.7M-13.7% | $6.9M-32.8% | $6.8M-26.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $58.7M+16.2% | $57.3M+19.7% | $54.0M+5.1% | $52.7M+19.9% | $50.6M+22.2% | $47.9M+9.2% | $51.4M+21.7% | $44.0M-5.7% |
| Accounts Receivable | $34.8M+7.6% | $34.4M-4.5% | $33.9M+15.6% | $30.9M+11.4% | $32.3M+4.1% | $36.1M+2.2% | $29.4M-7.5% | $27.8M+2.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $45.4M-0.1% | $45.3M+0.4% | $45.4M+0.8% | $45.3M+20.0% | $45.4M+21.1% | $45.1M+20.4% | $45.0M+19.8% | $37.8M+1.2% |
| Total Liabilities | $83.6M+1.5% | $90.9M+4.3% | $86.8M+0.6% | $84.8M+124.3% | $82.3M+125.7% | $87.1M+68.9% | $86.3M+63.2% | $37.8M-30.4% |
| Current Liabilities | $37.4M+24.9% | $43.1M+36.7% | $37.3M+27.5% | $33.7M+28.6% | $29.9M+45.3% | $31.5M+34.7% | $29.3M+23.4% | $26.2M-0.7% |
| Non-Current Liabilities | $46.2M-11.9% | $47.8M-14.0% | $49.4M-13.2% | $51.1M+340.4% | $52.4M+229.7% | $55.7M+97.1% | $57.0M+95.7% | $11.6M-58.5% |
| Long-Term Debt | $42.9M-9.8% | $44.2M-12.5% | $45.5M-11.6% | $46.5M+690.0% | $47.5M+376.1% | $50.5M+118.3% | $51.5M+118.0% | $5.9M-75.6% |
| Total Equity | $132.5M-4.3% | $129.6M-5.0% | $130.0M-3.0% | $137.3M+2.1% | $138.4M+3.9% | $136.4M+5.9% | $134.0M+6.9% | $134.5M+10.6% |
| Retained Earnings | -$38.2M-20.7% | -$40.8M-25.2% | -$40.3M-17.1% | -$32.9M+5.0% | -$31.7M+9.2% | -$32.6M+14.0% | -$34.4M+15.5% | -$34.6M+20.6% |
ULBI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.2M-80.0% | $2.3M-33.0% | $1.5M-51.1% | $198K-95.8% | $5.9M-33.5% | $3.4M+4258.0% | $3.0M+25.2% | $4.7M+633.9% |
| Depreciation & Amortization | $1.3M-6.6% | $1.3M-2.5% | $1.3M+10.9% | $1.4M+42.8% | $1.4M+39.6% | $1.4M+40.0% | $1.2M+22.0% | $994K+0.7% |
| Stock-Based Compensation | $90K-61.7% | -$1K-100.4% | N/A | $236K+38.8% | $235K+47.8% | $227K+41.0% | N/A | $170K+29.8% |
| Capital Expenditures | $453K-58.8% | $770K-14.0% | $882K+45.5% | $995K+67.5% | $1.1M+205.6% | $895K+140.6% | $606K-39.7% | $594K+11.2% |
| Free Cash Flow | $735K-84.8% | $1.5M-39.9% | $607K-75.1% | -$797K-119.2% | $4.8M-43.5% | $2.5M+645.9% | $2.4M+71.0% | $4.2M+391.8% |
| Investing Cash Flow | -$453K+58.8% | -$770K+14.0% | -$886K+98.2% | -$991K-66.8% | -$1.1M-205.6% | -$895K-140.6% | -$48.6M-4738.6% | -$594K-11.2% |
| Financing Cash Flow | -$3.0M-14.1% | -$2.1M-200.3% | -$687K-101.5% | -$651K+84.0% | -$2.7M+77.8% | -$687K-471.4% | $45.7M+15276.1% | -$4.1M-267.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ULBI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.9%+5.0pp | 21.3%-3.8pp | 24.9%+0.7pp | 22.2%-2.1pp | 23.9%-3.0pp | 25.1%-2.2pp | 24.2%-1.4pp | 24.3%-0.4pp |
| Operating Margin | 7.2%+2.5pp | -0.4%-7.2pp | -21.9%-25.2pp | -2.2%-3.6pp | 4.7%-4.5pp | 6.7%-3.0pp | 3.4%-4.8pp | 1.4%-4.0pp |
| Net Margin | 5.3%+3.5pp | -0.9%-4.6pp | -15.3%-15.8pp | -2.8%-3.5pp | 1.8%-5.1pp | 3.7%-3.2pp | 0.4%-6.0pp | 0.7%-2.7pp |
| Return on Equity | 1.9%+1.3pp | -0.4%-1.7pp | -5.7%-5.8pp | -0.9%-1.1pp | 0.6%-1.6pp | 1.4%-0.9pp | 0.1%-2.2pp | 0.2%-0.9pp |
| Return on Assets | 1.2%+0.8pp | -0.2%-1.0pp | -3.4%-3.5pp | -0.5%-0.7pp | 0.4%-1.4pp | 0.8%-0.8pp | 0.1%-1.5pp | 0.1%-0.6pp |
| Current Ratio | 2.87-0.4x | 2.56-0.7x | 2.83-0.5x | 2.99-0.3x | 3.31-0.8x | 3.22-0.8x | 3.32-0.5x | 3.30-0.1x |
| Debt-to-Equity | 0.320.0x | 0.340.0x | 0.350.0x | 0.34+0.3x | 0.34+0.3x | 0.37+0.2x | 0.38+0.2x | 0.04-0.2x |
| Asset Turnover | 0.220.0x | 0.210.0x | 0.220.0x | 0.200.0x | 0.220.0x | 0.230.0x | 0.20-0.1x | 0.210.0x |
| FCF Margin | 1.5%-8.4pp | 3.1%-1.7pp | 1.3%-4.3pp | -1.8%-13.5pp | 10.0%-10.0pp | 4.9%+5.9pp | 5.6%+2.4pp | 11.6%+15.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ultralife Corporation ULBI | FY2025 | $191.2M | -$5.9M | -3.1% | $104.3M | 42/100 |
| RF Industries Ltd RFIL | FY2025 | $80.6M | $75 | 0.0% | $90.1M | 41/100 |
| Espey Mfg. & Electronics Corp ESP | FY2026 | $46.1M | $11.2M | 24.2% | $172.0M | 72/100 |
| SKYX Platforms Corp. SKYX | FY2025 | $92.0M | -$33.4M | -36.3% | $149.0M | 33/100 |
| CBAK Energy Technology Limited CBAT | FY2025 | $195.2M | -$9.4M | -4.8% | $93.1M | 41/100 |
| NeoVolta Inc. NEOV | FY2026 | $13.3M | -$21.5M | N/A | $154.0M | 42/100 |
Where Ultralife Corporation Ranks
Frequently Asked Questions
What is Ultralife Corporation's annual revenue?
Ultralife Corporation (ULBI) reported $191.2M in total revenue for fiscal year 2025. This represents a 16.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ultralife Corporation's revenue growing?
Ultralife Corporation (ULBI) revenue grew by 16.2% year-over-year, from $164.5M to $191.2M in fiscal year 2025.
Is Ultralife Corporation profitable?
No, Ultralife Corporation (ULBI) reported a net income of -$5.9M in fiscal year 2025, with a net profit margin of -3.1%.
What is Ultralife Corporation's EBITDA?
Ultralife Corporation (ULBI) had EBITDA of -$403K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ultralife Corporation have?
As of fiscal year 2025, Ultralife Corporation (ULBI) had $9.3M in cash and equivalents against $45.5M in long-term debt.
What is Ultralife Corporation's gross margin?
Ultralife Corporation (ULBI) had a gross margin of 24.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ultralife Corporation's operating margin?
Ultralife Corporation (ULBI) had an operating margin of -3.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ultralife Corporation's net profit margin?
Ultralife Corporation (ULBI) had a net profit margin of -3.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ultralife Corporation's return on equity (ROE)?
Ultralife Corporation (ULBI) has a return on equity of -4.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ultralife Corporation's free cash flow?
Ultralife Corporation (ULBI) generated $7.1M in free cash flow during fiscal year 2025. This represents a -51.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ultralife Corporation's operating cash flow?
Ultralife Corporation (ULBI) generated $11.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ultralife Corporation's total assets?
Ultralife Corporation (ULBI) had $216.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ultralife Corporation's capital expenditures?
Ultralife Corporation (ULBI) invested $3.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ultralife Corporation spend on research and development?
Ultralife Corporation (ULBI) invested $10.4M in research and development during fiscal year 2025.
What is Ultralife Corporation's current ratio?
Ultralife Corporation (ULBI) had a current ratio of 2.83 as of fiscal year 2025, which is generally considered healthy.
What is Ultralife Corporation's debt-to-equity ratio?
Ultralife Corporation (ULBI) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ultralife Corporation's return on assets (ROA)?
Ultralife Corporation (ULBI) had a return on assets of -2.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ultralife Corporation's P/E ratio?
Ultralife Corporation (ULBI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $104.3M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ultralife Corporation's price-to-sales ratio?
Ultralife Corporation (ULBI) trades at 0.6x sales, its market capitalization divided by revenue of $187.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $104.3M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ultralife Corporation's Altman Z-Score?
Ultralife Corporation (ULBI) has an Altman Z-Score of 1.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ultralife Corporation's Piotroski F-Score?
Ultralife Corporation (ULBI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ultralife Corporation's earnings high quality?
Ultralife Corporation (ULBI) reported a net loss of $5.9M while generating $11.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ultralife Corporation cover its interest payments?
Ultralife Corporation (ULBI) reported an operating loss of $5.9M against $4.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ultralife Corporation?
Ultralife Corporation (ULBI) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.